Guideline for Human Papilloma Virus Testing in Head and Neck Carcinomas

February 9th, 2018

The Centers for Disease Control and Prevention estimates that in the US, there are more than 16,000 cases of Human PapillomaVirus (HPV)-positive OroPharyngeal Squamous Cell Carcinoma (OPSCC) per year and there has been a significant increase in incidence during the past several decades. Expression of tumor suppressor protein, known as p16, is highly correlated with infection with HPV in HNSCC. Accurate HPV assessment in head and neck cancers is becoming important as it significantly impacts clinical management. The College of American Pathologists convened a panel of experts and following review of evidence from over 400 peer reviewed articles, came up with the Guideline. This can be reviewed at www.oncoprescribe.com.  This guideline is recommended for all new Oropharyngeal Squamous cell carcinoma patients, but not routinely recommended for other head and neck carcinomas.